Differences Observed in Urinary Microbiota Among Patients With Bladder Cancer
March 31, 2020 07:03pm
By Massimo Lazzari, MD
Shilpa Gupta, MD, discusses the current role of immunotherapy in treating patients with bladder cancer and how biomarkers have become an unmet need.
Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the current role of immunotherapy in treating patients with bladder cancer and how biomarkers have become an unmet need.
Although immunotherapy options have been an improvement since there weren’t any new therapies added to the bladder cancer treatment paradigm for the last 40 years in this population, says Gupta, only 20% to 25% of patients respond to immunotherapy. Biomarkers, however, can identify patients that can be spared the risk of disease progression and financial toxicities by determining earlier on the patients that likely will not respond to single-agent checkpoint inhibitors. Gupta urges that we need to do a better job going forward at finding the patients who likely will or will not respond.